Langerhans cell histiocytosis in a patient with systemic lupus erythematosus: A clonal disease responding to treatment with cladribine, and cyclophosphamide

被引:9
作者
Robak, T [1 ]
Kordek, R [1 ]
Robak, E [1 ]
Bartkowiak, J [1 ]
Biernat, W [1 ]
Liberski, P [1 ]
Blonski, J [1 ]
机构
[1] Med Univ Lodz, Dept Hematol, PL-93512 Lodz, Poland
关键词
Langerhans cell histiocytosis; systemic lupus erythematosus; autoimmune diseases; molecular analysis; cladribine; cyclophosphamide;
D O I
10.1080/1042819021000015998-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Langerhans cell histiocytosis (LCH) is a rare neoplastic disease of specific dendritic cells which belong to the monocyte-macrophage system. The association of LCH with autoimmune disease is extremely rare and to our knowledge its coexistence with systemic lupus erythematosus (SLE) has not been described so far. We report a case of LCH affecting liver, spleen and abdomen lymph nodes, which developed in an adult female six years after diagnosis of SLE treated for a long time with prednisone. Histology showed infiltration of characteristic Langerhans cells with folded, grooved or lobulated nuclei with fine chromatin. In the background there were eosinophils, lymphocytes and CD-68-positive histiocytes. The neoplastic cells were S100p-immunopositive, but stained negatively for CD1a-probably as the result of overfixation of consulted material. CD-68 was present mostly in macrophages. Ultrastructurally, the tumour cells presented structures consistent with Birbeck granules. Clonal origin of neoplastic cells was shown using the HUMARA-PCR assay. The disease was refractory to treatment with high doses of prednisone and vincristine but complete response was achieved after treatment with caldribine combined with cyclophosphamide.
引用
收藏
页码:2041 / 2046
页数:6
相关论文
共 29 条
  • [1] NEUROBLASTIC DIFFERENTIATION OF METASTASES OF MEDULLOBLASTOMA TO EXTRACRANIAL LYMPH-NODE - AN ULTRASTRUCTURAL-STUDY
    ALWASIAK, J
    MIRECKA, B
    WOZNIAK, L
    LIBERSKI, PP
    [J]. ULTRASTRUCTURAL PATHOLOGY, 1991, 15 (06) : 647 - 654
  • [2] [Anonymous], WHO CLASSIFICATION T
  • [3] Baumgartner I, 1997, MED PEDIATR ONCOL, V28, P9, DOI 10.1002/(SICI)1096-911X(199701)28:1<9::AID-MPO3>3.0.CO
  • [4] 2-P
  • [5] Systemic lupus erythematosus and the risk of malignancy
    Cibere, J
    Sibley, J
    Haga, M
    [J]. LUPUS, 2001, 10 (06) : 394 - 400
  • [6] CLINE MJ, 1994, BLOOD, V84, P2840
  • [7] GENETIC-FACTORS PREDISPOSING TO CHRONIC LYMPHOCYTIC-LEUKEMIA AND TO AUTOIMMUNE-DISEASE
    CONLEY, CL
    MISITI, J
    LASTER, AJ
    [J]. MEDICINE, 1980, 59 (05) : 323 - 334
  • [8] Treatment of Langerhans cell histiocytosis with 2 chlorodeoxyadenosine
    Dimopoulos, MA
    Theodorakis, M
    Kostis, E
    Papadimitris, C
    Moulopoulos, LA
    AnastasiouNana, M
    [J]. LEUKEMIA & LYMPHOMA, 1997, 25 (1-2) : 187 - 189
  • [9] LANGERHANS CELL HISTIOCYTOSIS - DEFINITIVE DIAGNOSIS WITH THE USE OF MONOCLONAL-ANTIBODY-O10 ON ROUTINELY PARAFFIN-EMBEDDED SAMPLES
    EMILE, JF
    WECHSLER, J
    BROUSSE, N
    BOULLAND, ML
    COLOGON, R
    FRAITAG, S
    VOISIN, MC
    GAULARD, P
    BOUMSELL, L
    ZAFRANI, ES
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1995, 19 (06) : 636 - 641
  • [10] Giona F, 1997, CANCER, V80, P1786